KB105
Phase 1/2UNKNOWN 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
TGM-1 Related Autosomal Recessive Congenital Ichthyosis
Conditions
TGM-1 Related Autosomal Recessive Congenital Ichthyosis
Trial Timeline
Aug 27, 2019 → Mar 1, 2025
NCT ID
NCT04047732About KB105
KB105 is a phase 1/2 stage product being developed by Krystal Biotech for TGM-1 Related Autosomal Recessive Congenital Ichthyosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT04047732. Target conditions include TGM-1 Related Autosomal Recessive Congenital Ichthyosis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05735158 | Phase 2 | UNKNOWN |
| NCT04047732 | Phase 1/2 | UNKNOWN |